Status:
UNKNOWN
Comparative Effectiveness of Targeted Therapy in RA Patients
Lead Sponsor:
Hanyang University
Collaborating Sponsors:
Ministry of Health, Republic of Korea
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
19+ years
Brief Summary
The objective of a multicenter prospective observational study is to compare effectiveness and safety of biologic disease-modifying antirheumatic drugs and small molecular inhibitors in patients with ...
Detailed Description
This study is a multicenter prospective observational study to show non-inferiority of clinical efficacy for small molecular inhibitors after 48 week of treatment to biologic disease modifying anti-rh...
Eligibility Criteria
Inclusion
- Patients are included in this study if they are:
- 19 years or olders
- Patients who satisfy the 1987 American College of Rheumatology (ACR) or 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA
- Patients having moderately to severely active RA who are intolerant to csDMARDs including methotrexate and those who have never been exposed to bDMARDs or small molecular inhibitors before
- Patients who provide written consent to participate in this study
Exclusion
- Patients who are contraindicated to bDMARDs or small molecule inhibitor
- Patients who have plans for pregnancy or elective surgery
- Patients who had ever diagnosed with any malignancy or are treated for malginancy
- Patients who cannot voluntarily provie a written consent to participate in this study
- Patients who did not provide a written consent to participate in this study
Key Trial Info
Start Date :
April 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 19 2024
Estimated Enrollment :
506 Patients enrolled
Trial Details
Trial ID
NCT04449224
Start Date
April 27 2020
End Date
August 19 2024
Last Update
June 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanyang University
Seoul, South Korea, 04763